Crude Oil Prices Jump Over 3% To Near $84 As Middle East Conflict Raises Supply Concerns
Stocks To Watch On February 26: Lupin, Angel One, Zydus Lifesciences, Rail Vikas Nigam In Focus
Last Updated: 26th February 2026 - 11:09 am
Summary:
Shares of Lupin, Angel One, Zydus Lifesciences, Shaily Engineering Plastics, KSB, Sanofi India, KP Energy, and Rail Vikas Nigam are in focus on February 26 following quarterly earnings, regulatory actions, project awards, and corporate announcements made to the exchanges.
Join 5paisa and stay updated with Market News
Sanofi India reported a 32.4% year-on-year (YoY) decline in Q4 profit at ₹61.7 crore compared with ₹91.3 crore in the previous year. Revenue fell 18.5% to ₹419.8 crore from ₹514.9 crore.
KSB posted a 10.8% YoY increase in consolidated Q4 profit at ₹81 crore versus ₹73.1 crore. Revenue rose 7.9% to ₹784 crore from ₹726.4 crore. The company disclosed an impact of ₹25.5 crore on account of the new labour code, compared with nil in the year-ago period.
Sanofi Consumer Healthcare India recorded a 50.1% YoY rise in Q4 profit at ₹66.5 crore against ₹44.3 crore. Revenue increased 47% to ₹251 crore from ₹170.7 crore.
Foseco India reported a 35.5% drop in consolidated Q4 profit at ₹12.6 crore compared with ₹19.5 crore earlier. Revenue climbed 37% to ₹186.9 crore from ₹136.5 crore, while exceptional loss stood at ₹16.86 crore versus nil last year.
Nova Iron & Steel, Vesuvius India, John Cockerill India, and Indrayani Biotech are also scheduled to announce their quarterly results on February 26.
Corporate And Regulatory Updates
Lupin said the Goods and Services Tax Department, Maharashtra, initiated inspection and search proceedings at its registered office on February 25, seeking documents related to GST payments and input tax credit claims. The company stated that the inspection has no impact on its financials, operations, or other activities.
Shaily Engineering Plastics received an order worth ₹423 crore from a domestic pharmaceutical company.
Zydus Lifesciences plans to launch Semaglutide injection under the brand names SEMAGLYN, MASHEMA, and ALTERM in India upon patent expiry. The Drug Controller General of India had approved the manufacturing and marketing of Semaglutide injection for the treatment of Type 2 Diabetes Mellitus and obesity.
KP Energy received a Letter of Award from Enerparc Energy for the development of a 40.8 MW wind-solar hybrid power project in Gujarat.
Rail Vikas Nigam secured a Letter of Award from NMDC for the development of a township at Kirandul, Chhattisgarh, valued at ₹371.69 crore.
Other Developments
SBI Life Insurance Company declared an interim dividend of ₹2.7 per equity share for FY26.
Angel One trades ex-date for stock split on February 26 and remains in the F&O ban list as per exchange data.
These disclosures and earnings announcements are expected to keep the above stocks in focus during trading on February 26
- Flat ₹20 Brokerage
- Next-gen Trading
- Advanced Charting
- Actionable Ideas
Trending on 5paisa
02
5paisa Capital Ltd
03
5paisa Capital Ltd
Indian Market Related Articles
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.